+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Acute Respiratory Distress Syndrome Market by Type (Diagnostics, Treatment), Cause (Direct Lung Injury, Indirect Lung Injury), End-user - Forecast 2024-2030

  • PDF Icon

    Report

  • 199 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967555
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Acute Respiratory Distress Syndrome Market grew from USD 2.56 billion in 2023 to USD 2.72 billion in 2024. It is expected to continue growing at a CAGR of 6.13%, reaching USD 3.89 billion by 2030.

ARDS is a type of respiratory failure that occurs when fluid is produced in the tiny, elastic air sacs (alveoli) in the lungs. The fluid controls the lungs from filling with sufficient air, which means less oxygen reaches the bloodstream. Products and services in the ARDS market are applied in critical care settings, including intensive care units (ICUs) in hospitals and emergency departments, where patients with severe respiratory failure receive treatment. Several factors influence the growth of the ARDS market. The increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections, drives the demand for effective treatments. Technological advancements in mechanical ventilation and supportive therapies contribute to market growth. Additionally, the heightened focus on research and development of new pharmaceuticals and the expanding awareness and understanding of ARDS among healthcare providers propel the market forward. Despite growth prospects, the ARDS market faces challenges such as high treatment costs and limited accessibility to advanced care in low-income regions that restrict market expansion. Furthermore, the complexity of ARDS, variability in patient response to treatments, and a still-evolving understanding of its pathophysiology make developing universally effective treatments challenging. On the other hand, the development of personalized medicine approaches targeting the molecular and immunological underpinnings of ARDS presents a significant opportunity. Additionally, expanding markets in emerging economies, with increasing healthcare infrastructure investments, offer new avenues for growth. Collaboration between academic, research institutions, and industry in developing innovative therapies also opens up potential opportunities.

Regional Insights

The Americas, particularly the United States and Canada, have shown a significant need for advanced treatments for acute respiratory distress syndrome (ARDS). The high prevalence of ARDS in these regions, compounded by robust healthcare infrastructure, has facilitated substantial market growth. Customer purchasing behavior in the Americas tends to lean towards innovative, evidence-based treatments, reflecting a trust in advanced medical technology and pharmaceutical interventions. In South America, the market for ARDS treatments and diagnostics is gradually expanding, with Brazil and Argentina at the forefront, investing in healthcare infrastructure and clinical research. Europe represents a significant market for ARDS, with Western European countries are at forefront in terms of research, treatment adoption, and market revenues. The region benefits from strong healthcare systems and widespread adoption of advanced therapeutics. Moreover, numerous initiatives and collaborations aim to address ARDS, elevating the urgency for effective management strategies. In contrast, the Middle East and Africa face distinctive challenges, including limited access to healthcare services and a lack of specialized medical facilities in some areas. However, growing awareness and increasing healthcare expenditures are gradually improving the ARDS treatment landscape in these regions. The Asia-Pacific region is witnessing rapid market growth for ARDS treatments and diagnostics, fueled by rising healthcare spending and population growth. China, Japan, and India are conducting this growth due to their large populations and increasing prevalence of respiratory diseases. The region is also seeing a significant uptick in research initiatives and adoption of cutting-edge treatments. Government initiatives to improve healthcare systems are further propelling the market forward in the APAC region.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Acute Respiratory Distress Syndrome Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
  • Advancements in mechanical ventilation and supportive therapies
  • Rising focus on research and development of new pharmaceuticals

Market Restraints

  • High treatment costs and limited accessibility to advanced care

Market Opportunities

  • Ongoing development of personalized medicine approaches
  • Increasing government initiatives and healthcare infrastructure investments

Market Challenges

  • Regulatory complexities for the approval of new therapies and devices

Market Segmentation Analysis

  • Type: Increasing need for diagnostics due to its potential for precision medicine application
  • End-user: Expanding preference for hospitals for management of ARDS

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acute Respiratory Distress Syndrome Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acute Respiratory Distress Syndrome Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

BioAegis scores USD 20millon BARDA contract to develop ARDS therapy

BioAegis Therapeutics secured a USD 20 million contract from the US Biomedical Advanced Research and Development Authority (BARDA) for the treatment of Acute Respiratory Distress Syndrome (ARDS), under its DRIVe initiative, to advance the development of plasma gelsolin therapy.

Veru Inc., Reaches Agreement With FDA on a New Phase III Clinical Trial for Sabizabulin for Broader Indication Hospitalized Adult Patients with any Type of Viral Acute Respiratory Distress Syndrome ARDS

Veru Inc. announced the design of a new Phase III clinical trial study to evaluate sabizabulin plus standard of care treatment in an expanded patient population, hospitalized adult patients having any type of virus causing ARDS.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acute Respiratory Distress Syndrome Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Acute Respiratory Distress Syndrome Market, highlighting leading vendors and their innovative profiles. These include APEPTICO GmbH, Armstrong Medical Ltd., Athersys, Inc., Bayer AG, Besmed Health Business Corp., Drägerwerk AG & Co. KGaA, EUROSETS S.R.L., F. Hoffmann-La Roche Ltd., Fisher & Paykel Healthcare Corporation Limited, GE HealthCare, Getinge AB, Hamilton Medical AG, HEALIOS K.K., LivaNova PLC, Novartis AG, NRx Pharmaceuticals, Pfizer Inc., Sun Pharmaceutical Industries Limited, Terumo Medical Corporation, United Therapeutics Corporation, and WEINMANN Emergency Medical Technology GmbH + Co. KG.

Market Segmentation & Coverage

This research report categorizes the Acute Respiratory Distress Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

  • Diagnostics
  • Treatment

Cause

  • Direct Lung Injury
  • Indirect Lung Injury

End-user

  • Hospital
  • Speciality Clinics

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
5.1.1.2. Advancements in mechanical ventilation and supportive therapies
5.1.1.3. Rising focus on research and development of new pharmaceuticals
5.1.2. Restraints
5.1.2.1. High treatment costs and limited accessibility to advanced care
5.1.3. Opportunities
5.1.3.1. Ongoing development of personalized medicine approaches
5.1.3.2. Increasing government initiatives and healthcare infrastructure investments
5.1.4. Challenges
5.1.4.1. Regulatory complexities for the approval of new therapies and devices
5.2. Market Segmentation Analysis
5.2.1. Type: Increasing need for diagnostics due to its potential for precision medicine application
5.2.2. End-user: Expanding preference for hospitals for management of ARDS
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Acute Respiratory Distress Syndrome Market, by Type
6.1. Introduction
6.2. Diagnostics
6.3. Treatment
7. Acute Respiratory Distress Syndrome Market, by Cause
7.1. Introduction
7.2. Direct Lung Injury
7.3. Indirect Lung Injury
8. Acute Respiratory Distress Syndrome Market, by End-user
8.1. Introduction
8.2. Hospital
8.3. Speciality Clinics
9. Americas Acute Respiratory Distress Syndrome Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Acute Respiratory Distress Syndrome Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Acute Respiratory Distress Syndrome Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. BioAegis scores USD 20millon BARDA contract to develop ARDS therapy
12.3.2. Veru Inc., Reaches Agreement With FDA on a New Phase III Clinical Trial for Sabizabulin for Broader Indication Hospitalized Adult Patients with any Type of Viral Acute Respiratory Distress Syndrome ARDS
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET DYNAMICS
FIGURE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIRECT LUNG INJURY, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIRECT LUNG INJURY, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INDIRECT LUNG INJURY, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INDIRECT LUNG INJURY, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 26. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 27. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 28. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 29. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 30. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 31. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 32. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 33. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 34. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 35. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 36. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 37. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 38. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 39. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 40. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 41. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 42. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 43. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 44. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 45. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 46. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 47. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 48. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 49. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 50. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 51. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 52. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 53. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 54. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 55. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 56. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 57. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 58. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 59. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 60. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 61. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 62. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 63. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 64. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 66. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 68. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 70. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 72. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 73. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 74. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 75. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 76. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 77. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 78. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 79. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 80. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 81. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 82. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 83. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 84. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 85. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 86. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 87. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 88. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 89. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 90. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 91. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 92. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 93. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 94. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 95. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 96. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 97. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 98. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 99. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 100. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 101. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 102. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 103. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 104. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 105. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 106. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 107. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 108. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 109. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 110. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 111. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 112. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 113. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 114. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 115. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 116. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 117. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 118. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 119. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 120. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 121. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 122. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 123. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 124. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 125. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 126. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 127. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 128. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 129. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 130. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 131. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 132. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 133. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 134. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 135. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 136. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 137. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 138. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 139. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 140. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 141. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 142. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 143. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 144. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 153. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 154. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 155. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 156. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 157. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 158. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 159. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 160. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 161. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 162. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 163. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 164. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 165. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 166. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 167. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 168. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 169. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 170. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 171. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 172. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 173. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 174. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 175. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 176. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 177. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 178. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 179. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 180. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 181. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 182. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 183. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 184. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 185. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 186. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 187. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 188. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 189. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 190. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 191. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 192. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 193. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 194. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 195. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 196. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 197. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 198. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 199. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 200. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 201. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 202. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 203. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 204. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 205. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 206. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 207. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 208. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 209. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 210. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 211. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 212. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 213. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 214. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 215. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 216. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 217. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 218. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 219. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 220. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 221. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 222. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 223. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 224. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 225. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 226. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 227. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 228. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 229. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 230. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 232. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 234. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 236. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 238. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 240. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 242. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 243. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 244. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 245. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 246. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 247. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 248. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 249. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 250. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 251. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 252. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 253. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 254. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 255. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 256. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 257. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 258. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 259. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 260. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 261. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 262. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 263. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 264. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 265. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 266. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 274. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
TABLE 276. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 278. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 279. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
TABLE 280. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • APEPTICO GmbH
  • Armstrong Medical Ltd.
  • Athersys, Inc.
  • Bayer AG
  • Besmed Health Business Corp.
  • Drägerwerk AG & Co. KGaA
  • EUROSETS S.R.L.
  • F. Hoffmann-La Roche Ltd.
  • Fisher & Paykel Healthcare Corporation Limited
  • GE HealthCare
  • Getinge AB
  • Hamilton Medical AG
  • HEALIOS K.K.
  • LivaNova PLC
  • Novartis AG
  • NRx Pharmaceuticals
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Terumo Medical Corporation
  • United Therapeutics Corporation
  • WEINMANN Emergency Medical Technology GmbH + Co. KG

Methodology

Loading
LOADING...

Table Information